Date: SEP 28 1992

From: Bryan B. Mitchell
Principal Deputy Inspector General

Subject: Audit of Six Ulcer Treatment Drugs Reimbursed Under the Illinois Medicaid Prescription Drug Program (A-06-92-00008)

To: William Toby, Jr.
Acting Administrator
Health Care Financing Administration

This memorandum alerts you to the issuance on September 29, 1992, of our final report. A copy is attached.

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) requires State Medicaid agencies to operate drug use review (DUR) programs on an ongoing basis. These programs are intended to assess actual patient drug use against predetermined standards. One of the standards recognized by OBRA '90 is the manufacturers' recommended dosages.

The manufacturers of six ulcer treatment drugs provide recommendations for the prescribing of their drug products in the treatment of gastric and duodenal ulcers. The Illinois Department of Public Aid (State agency), however, did not have any restrictions pertaining to the manufacturers' recommended dosages for ulcer treatment drugs. Accordingly, our review showed that about $5.82 million (Federal share $2.91 million) in cost savings could have been realized for Calendar Year 1990 had the State agency limited payment for these drugs to the amount needed to pay for the manufacturers' recommended dosages.

We are recommending that the State agency establish procedures to limit the payment for these ulcer treatment drugs to the manufacturers' recommended dosages. We believe that the Health Care Financing Administration (HCFA) should take an active role in encouraging the State agency to implement our recommendation.

In a letter dated June 16, 1992, the Director of the Illinois Department of Public Aid stated that our report had merit. The Director advised that the State agency was actively involved in the development of a DUR program that would include a prospective review of ulcer treatment drugs.
Because ulcer treatment drugs are among the most commonly prescribed Medicaid drugs, we are performing this review at eight randomly selected States to quantify the potential cost savings available nationwide to the Medicaid program by limiting the reimbursements for these drugs to the manufacturers' dosage. When we have completed our reviews of the remaining States, we will be issuing a consolidated report to HCFA on this subject.

For further information, contact:

Donald L. Dille  
Regional Inspector General  
for Audit Services, Region VI  
(214) 767-8414

Attachment
AUDIT OF SIX ULCER TREATMENT DRUGS REIMBURSED UNDER THE MEDICAID PRESCRIPTION DRUG PROGRAM

ILLINOIS DEPARTMENT OF PUBLIC AID
SPRINGFIELD, ILLINOIS

SEPTEMBER 1992    A-06-92-00008
Our Reference: Common Identification No. A-06-92-00008

Mr. Phil Bradley
Director
Illinois Department of Public Aid
100 South Grand Avenue East
Springfield, Illinois 62762-0001

Dear Mr. Bradley:

This report provides you with the results of our audit of six ulcer treatment drugs reimbursed under the Medicaid prescription drug program of the Illinois Department of Public Aid (State agency). The objective of our audit was to determine the extent that ulcer treatment drugs were paid for by the Medicaid program in dosages that exceeded the manufacturers' recommendations. The results were used to estimate the potential cost savings available through limiting reimbursements to the manufacturers' recommendations.

This audit was conducted as a part of a nationwide review of ulcer treatment drugs. The purpose of this nationwide audit is to develop a projection of the potential cost savings that could be realized if manufacturers' recommendations were followed. Illinois was 1 of 8 States randomly chosen for review from a universe of 42 States that did not have restrictions on ulcer treatment drugs.

The State agency has an opportunity to establish procedures to limit payments for the six ulcer treatment drugs to the manufacturers' recommended dosages. We found that the recommended dosages were exceeded in 75 of the 200 sampled cases. We estimate that establishing restrictions based on manufacturers' recommendations could result in savings of about $5,821,297 (Federal share $2,910,649).

While there is no current requirement for limiting reimbursements to manufacturers' recommendations, we believe that the establishment of such procedures can be cost effective in Illinois. For example, the State of Texas has already set up a prospective drug use review (DUR) system at a cost of about
$180,000 and has estimated first year savings of $6 million for its ulcer treatment drugs. Therefore, we are recommending that the State agency consider establishing procedures to limit payment for the six ulcer treatment drugs to the amounts paid for manufacturers' recommended dosages.

The Director of the Illinois Department of Public Aid responded to our draft report in a letter dated June 16, 1992. The Director stated that our report had merit and that the State agency was actively involved in the development of a DUR program that would include a prospective review of ulcer treatment drugs. The full text of the Director's comments are included as Appendix C to this report.

BACKGROUND

Medicaid is a federally-aided, State operated and administered program that provides medical benefits to low income persons who are aged, blind, disabled, or members of families with dependent children where one parent is absent, incapacitated, or unemployed. The program, authorized by title XIX of the Social Security Act, requires States to provide certain medical services and permits them to provide other services, such as outpatient prescription drugs, on an optional basis. Federal oversight is the responsibility of the Health Care Financing Administration (HCFA) of the Department of Health and Human Services (HHS).

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) requires State Medicaid agencies to operate DUR programs on an ongoing basis. These programs are intended to assess actual patient drug use data against predetermined standards which are contained in the compendia listed in OBRA '90.

Tagamet, Zantac, Pepcid, and Axid belong to a classification of drugs known as histamine H₂-receptor antagonists (or H₂ antagonists). These drugs are prescribed for the treatment of gastric and duodenal ulcers and have reduced the need for stomach ulcer surgery. Unlike earlier drugs which tried to neutralize excess stomach acid, these drugs reduce the actual flow of acid. Carafate and Prilosec (formerly Losec) are not H₂ antagonists, but they are related ulcer treatment drugs and are prescribed in a similar manner.

Pharmaceutical publications such as Facts and Comparisons and Physician's Desk Reference, as well as prescribing and product information (package inserts) published by the manufacturers, provide information concerning recommended dosages for these drugs. These resources show that the manufacturers recommend that these drugs be prescribed in full dosages during an active treatment period of 4 to 8 weeks to promote healing of the ulcer.
After the active treatment period, the manufacturers recommend that the dosages be reduced by 67 percent for Tagamet and 50 percent for Zantac, Pepcid, Axid, and Carafate as maintenance therapy to prevent recurrence. There was no manufacturer recommended maintenance therapy for Prilosec. These resources did not clearly define the manufacturers' recommendation regarding the length of the maintenance therapy period.

There are circumstances in which the maintenance level dosages are inappropriate. For example, the drugs are used in the treatment of pathological hypersecretory conditions or "Zollinger-Ellison syndrome." Treatment of this rare disease with H₂ antagonists continues for as long as clinically necessary with no active or maintenance treatment periods.

Limiting the prescribing of these drugs to the medically necessary dosages recommended by the manufacturers offers potential cost savings because of their popularity and price. In recent years, Zantac and Tagamet have ranked as the top two drugs in terms of sales revenue among drugs sold worldwide and ranked in the top five in terms of sales revenue in the United States market. Using the average wholesale price, a 30-day supply of ulcer treatment drugs at active dosage levels costs from $60 to $120.

SCOPE

The objective of our audit, which was conducted in accordance with generally accepted government auditing standards, was to determine the extent that ulcer treatment drugs were paid for by the Medicaid program in dosages that exceeded the manufacturers' recommended dosages. Achieving our audit objective did not require that we review the entire internal control structure of the State agency. Therefore, we reviewed only those controls relating to the utilization of the ulcer treatment drugs selected for review.

To accomplish our objective, we reviewed various drug compendia including, Facts and Comparisons, Physician's Desk Reference, American Hospital Formulary Service, and United States Pharmacopeial Drug Information regarding manufacturers' recommended dosages and strengths for the drugs selected for review. We also examined product information (package inserts) for the drugs.

The State agency's computerized Medicaid prescription drug payment records contained 74,437 unduplicated Medicaid recipients who had prescriptions for Tagamet, Zantac, Pepcid, Axid,
Carafate, or Prilosec during Calendar Year (CY) 1990. Of these, we randomly selected a sample of 200 recipients. Our review was performed during November 1991 through March 1992.

Our review did not include an evaluation of the medical necessity of dosages for ulcer treatment drugs received by the 200 sample Medicaid recipients. Therefore, our savings estimate did not consider those situations where manufacturers' recommended dosages for the drugs were exceeded due to medical necessity. Additionally, the savings estimate did not consider increases due to inflation and program growth since 1990.

RESULTS OF AUDIT

The State agency has an opportunity to establish procedures to limit payments for the six ulcer treatment drugs to the manufacturers' recommended dosages. Although the manufacturers recommended that dosages be reduced by 50 percent to 67 percent after a 4 to 8 week active treatment period, we found that the recommended dosages were exceeded in 75 of the 200 sampled cases. We estimate that establishing restrictions based on manufacturers' recommendations could result in savings of about $5,821,297 (Federal share $2,910,649).

The State of Illinois did not have restrictions in place to limit payment for the six ulcer treatment drugs to the manufacturers' recommended dosages. We believe that the establishment of a prospective DUR program that limits reimbursement for ulcer treatment drugs to the manufacturers' recommendations can be cost effective in Illinois. For example, the State of Texas has already set up a prospective DUR system at a cost of about $180,000 and has estimated savings of $6 million during the State's Fiscal Year (FY) 1991 for its ulcer treatment drugs. In response to an Office of Inspector General (OIG) audit, the State of Arkansas agreed that ulcer treatment drugs were overprescribed and overutilized and implemented a cost containment program for ulcer treatment drugs. Therefore, we are recommending that the State agency consider establishing prospective DUR procedures to limit payment for the six ulcer treatment drugs to the amount needed to pay for the manufacturers' recommended dosages.

ILLINOIS' CURRENT PROCEDURES

A State agency official advised us that there were no restrictions in place to limit reimbursements for these drugs to the manufacturers' recommended dosages. We believe that Illinois should consider establishing a prospective DUR to limit payments for ulcer treatment drugs to the manufacturers' recommended dosages. The limitation should not be imposed in cases where
continued active treatment is necessary based on physicians' authorizations of medical necessity. Payments should be denied, however, for active treatment dosages that extend beyond the active treatment period for claims that are not supported by physicians' statements of medical necessity.

RESULTS OF REVIEW OF A SAMPLE OF MEDICAID RECIPIENTS TO DETERMINE POTENTIAL COST SAVINGS

The State agency's computerized Medicaid prescription drug payment file contained 74,437 unduplicated Medicaid recipients who had prescriptions for Tagamet, Zantac, Pepcid, Axid, Carafate, or Prilosec during CY 1990. Of these, we randomly selected a sample of 200 recipients and found that dosages in 74 instances were not reduced when the period of expected active treatment ended and the maintenance therapy began. In addition, there was one instance where the active treatment dosages exceeded the manufacturers' recommended dosages. In summary, 75 of the 200 Medicaid recipients in the sample received dosages that exceeded the manufacturers' recommended dosages. The remaining 125 recipients in the sample received dosages equal to or lower than the manufacturers' recommended dosages. (See Appendix A for a description of our sampling methods.)

The total amount paid by Medicaid on behalf of the 200 sampled recipients for the drugs was $67,903. The applicable potential cost savings for the 200 recipients was $15,641 or about 23 percent of the Medicaid paid amount. Using this data, the estimated annual savings would have been $5,821,297 (Federal share $2,910,649) if Illinois had limited dosages to manufacturers' recommendations. (See Appendices for computation of our sample results.)

In calculating the potential cost savings, we determined the difference between the number of tablets paid for and the number of tablets recommended by the manufacturers for each prescription. Then we multiplied this difference (number of tablets) by the drug price per tablet paid by Medicaid for the prescription. This calculation was made for both active and maintenance treatment periods. The results were combined into one potential cost savings amount for the sampled recipients.
The manufacturers' recommended daily dosages, which we used in our calculations, are shown as follows:

<table>
<thead>
<tr>
<th>DRUG</th>
<th>ACTIVE CONDITIONS</th>
<th>MAINTENANCE THERAPY</th>
<th>REDUCTION IN DOSAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tagamet</td>
<td>1200 mg</td>
<td>400 mg</td>
<td>67%</td>
</tr>
<tr>
<td>Zantac</td>
<td>300 mg</td>
<td>150 mg</td>
<td>50%</td>
</tr>
<tr>
<td>Pepcid</td>
<td>40 mg</td>
<td>20 mg</td>
<td>50%</td>
</tr>
<tr>
<td>Axid</td>
<td>300 mg</td>
<td>150 mg</td>
<td>50%</td>
</tr>
<tr>
<td>Carafate</td>
<td>4 g</td>
<td>2 g</td>
<td>50%</td>
</tr>
<tr>
<td>Prilosec</td>
<td>20 mg</td>
<td>None</td>
<td>100%</td>
</tr>
</tbody>
</table>

Since these drugs are packaged in several different strengths, we determined the total number of tablets needed to equate to the recommended dosage levels. For example, if a physician prescribed Tagamet in 400 mg tablets, the number of tablets per day allowed in our calculations would be 3 (1200 mg divided by 400 mg) for active treatment or 1 (400 mg divided by 400 mg) for maintenance therapy.

We reviewed the manufacturers' recommended active treatment periods for various illnesses and concluded that a maximum of 8 weeks would be appropriate since, except for special circumstances, it represents the maximum active treatment period for the drugs. Therefore, in our calculations we used 62 days (the maximum number of days in a 2-month supply) as the applicable active treatment period. We believe that this period is reasonable because for certain illnesses the manufacturers recommended shorter active treatment periods. For example, the manufacturer of Tagamet states in its prescribing information bulletin (TG:L83) regarding treatment of active duodenal ulcer, "...while healing with Tagamet often occurs during the first week or two, treatment should be continued for 4-6 weeks unless healing has been demonstrated by endoscopic examination."

The State agency's computerized Medicaid prescription drug payment records did not contain information indicating the number of days supply that a prescription represented. Because of this, we reviewed each prescription, including the fill date of the next prescription, and judgmentally determined the number of days supply that the prescription provided.

We allowed one active treatment period for each different drug received by the Medicaid recipients. We started the count of days for determining the active treatment period on October 1, 1989, 3 months prior to the beginning of our review period. By doing so, we were able to determine whether a recipient receiving one of the drugs in the first month of our review period had already completed the active treatment.
restarted the count of days for determining an active treatment period if there was a break in treatment of 30 days or more before completing the active treatment period. We recognize that in special circumstances the active treatment period could extend beyond 62 days. For purposes of this study, however, we did not consider such special cases.

With regard to the maintenance treatment period, we did not set any limitations on the number of days, because there were no clearly defined manufacturers' recommendations regarding the termination of maintenance therapy.

ULCER TREATMENT DRUG LIMITATION PROGRAMS IN TWO STATES

The State of Texas has a program for ulcer treatment drugs which has produced significant savings consistent with good medical practice. Under the program, Medicaid recipients are limited to acute dosage levels of ulcer treatment drugs for up to 62 days. The dispensing pharmacist is able to determine whether a recipient has reached or exceeded the end of a 62-day active treatment period by calling a toll-free 800 number (using a touch-tone phone) directly linked to the profile data for each recipient. Texas State agency officials estimated that the personal computer based voice response system, that cost approximately $100,000, saved the Medicaid program approximately $6 million during State FY 1991.

The physicians are able to override the 62-day active treatment limit for higher dosage levels by writing the diagnosis on the face of a prescription. The pharmacist must submit a copy of the prescription to be reimbursed.

We performed a similar audit of ulcer treatment drugs within the Arkansas Medicaid program for CY 1989. Our audit showed the potential for cost savings of about $1.27 million (Federal share $940,594) by limiting reimbursement to the manufacturers' recommended dosages. The Arkansas audit was limited to Tagamet, Zantac, and Pepcid.

The Administrator of the Arkansas Pharmacy Program agreed with the findings of our audit and indicated that the ulcer treatment drugs were overprescribed and overutilized. The Administrator advised that the State was implementing a cost containment program for ulcer treatment drugs and that the State planned to have a prospective review program by January 1993.

RECOMMENDATIONS

We recommend that the State agency consider implementing procedures to limit the payment for all ulcer treatment drugs to
the amount needed to pay for the manufacturers' recommended dosages.

AUDITEE COMMENTS

The Director of the Illinois Department of Public Aid responded to our draft report in a letter dated June 16, 1992. The Director stated that our report had merit and that the State agency was actively involved in the development of a DUR program that would center on ulcer treatment drugs. The Director advised that the program will limit payment for all ulcer treatment drugs to the manufacturers' recommended dosages.

Final determination as to actions to be taken on all matters reported will be made by the HHS official named below. We request that you respond to the recommendations in this report within 30 days from the date of this letter to the HHS official named below, presenting any comments or additional information that you believe may have a bearing on his final decision.

In accordance with the principles of the Freedom of Information Act (Public Law 90-23), OIG, Office of Audit Services (OAS) reports issued to the Department's grantees and contractors are made available, if requested, to members of the press and general public to the extent information contained therein is not subject to exemptions in the Act which the Department chooses to exercise. (See 45 CFR Part 5.)

To facilitate identification, please refer to the above common identification number in all correspondence relating to this report.

Sincerely,

DONALD L. DILLE
Regional Inspector General for Audit Services

Direct Reply To:

Associate Regional Administrator for Medicaid, Region V
Health Care Financing Administration
Department of Health & Human Services
105 West Adams St.
14 - 16th Floors
Chicago, Illinois 60603
SAMPLE DESCRIPTION

Sample Objective: Project potential cost savings for excess Medicaid drug utilization attributable to Illinois Medicaid recipients who received the ulcer treatment drugs Tagamet, Zantac, Pepcid, Avid, Carafate, or Prilosec for CY 1990.

Sample Information: Total expenditures for the Illinois Medicaid outpatient prescription drug program were almost $88 million during the period January 1, 1990 through December 31, 1990.

Population: The sampling population was 74,437 unduplicated Medicaid recipients who received Tagamet, Zantac, Pepcid, Avid, Carafate, or Prilosec during the 12-month period ending December 31, 1990.

Sample Design: Simple random sampling was used to select the sample items.

Sample Size: A sample of 200 Medicaid recipients who received Tagamet, Zantac, Pepcid, Avid, Carafate, or Prilosec was taken.

Source of Random Numbers: The OAS Statistical Sampling Software was used to determine the random numbers for drawing the sample.

Characteristics to be Measured: From our examination of the Illinois Medicaid payment history tapes, we calculated the per tablet price for each prescription received by the Medicaid recipients in our sample. When the dosages and/or duration of treatment exceeded the manufacturers' recommendations, we computed a dollar value for the excess drugs used. This value was used to determine the cost savings that would have been realized if there had been a control in place to limit payments for Tagamet, Zantac, Pepcid, Avid, Carafate, or Prilosec tablets to the manufacturers' recommended dosages and durations of treatment.

Other Evidence: None.
Extrapolation: The total amount paid by Medicaid on behalf of the 200 sampled recipients for the 6 drugs was $67,903. The potential cost savings for the 200 recipients was $15,641 or about 23 percent of the Medicaid paid amount. Using this data and a 90 percent confidence level, the lower limit for our savings estimate was $4,555,859, the upper limit was $7,086,735, and the mid-point estimate was $5,821,297.
## SAMPLE RESULTS

<table>
<thead>
<tr>
<th>Sample Population</th>
<th>74,437</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Unduplicated Medicaid recipients receiving Tagamet, Zantac, Pepcid, Axd, Carafate, or Prilosec during CY 1990)</td>
<td></td>
</tr>
<tr>
<td>Standard Sample Size</td>
<td>200</td>
</tr>
<tr>
<td>Number of Sample Recipients Receiving Dosages in Excess of the Manufacturers' Recommended Dosages</td>
<td>75</td>
</tr>
<tr>
<td>Value of Sample</td>
<td>$67,903</td>
</tr>
<tr>
<td>Total Value of Dosages in Excess of Manufacturers' Recommendations</td>
<td>$15,641</td>
</tr>
<tr>
<td>Total Adjusted Value of Sample</td>
<td>$52,262</td>
</tr>
<tr>
<td>At the 90 percent confidence level:</td>
<td></td>
</tr>
<tr>
<td>Upper Limit</td>
<td>$7,086,735</td>
</tr>
<tr>
<td>Lower Limit</td>
<td>$4,555,859</td>
</tr>
<tr>
<td>Estimated Total Annual Savings</td>
<td>$5,821,297</td>
</tr>
<tr>
<td>Federal Share</td>
<td>$2,910,649</td>
</tr>
</tbody>
</table>
June 16, 1992

Mr. Donald L. Dille
Regional Inspector General
HHS/OIG Office of Audit Services
110 Commerce, Room 4E1A
Dallas, Texas 75242

RE: A-06-92-00008

Dear Mr. Dille:

This letter is in response to your letter of April 13, 1992. An exit conference was held on May 28, 1992 with Paul Chesser from the Little Rock Office. The Department has reviewed the draft report on the "Audit of Six Ulcer Treatment Drugs Reimbursed Under the Medicaid Prescription Drug Program". Our comments to your report are below:

Recommendation 1: We recommend that the State Agency consider implementing procedures to limit the payment for all ulcer treatment drugs to the manufacturers' recommended dosages.

State Agency Response: We believe that the report has merit. As stated in the report, Illinois does not presently limit reimbursement for these drugs based on the manufacturers' recommended dosages, but rather on a 30 day supply. The Division of Medical Programs performed an initial review of the cost incurred from these medications in FY'92. If 20% were inappropriately prescribed, approximately $6.6 million in spending could have been avoided. The Department has been actively involved in the development of the mandated Drug Use Review (DUR) program. Much of the internal DUR activity is centered on a module that will prospectively and retrospectively review H2 antagonists and anti-ulcer drugs.
As with the Arkansas Pharmacy Program, Illinois' plan is to implement a Prospective Drug Use Review program that will limit payment for all ulcer treatment drugs to the manufacturers' recommended dosages. We have set the implementation date for January 1, 1993. However, we feel there are still various difficulties that must be overcome and this process will not occur overnight. We believe adding this cost containing enhancement to the paid claims program is not impossible to achieve.

Texas uses an Automated Voice Response System (AVRS) for pharmacies to obtain approval for extended ulcer treatment. We feel that an AVRS used solely for one specific class of drugs is inappropriate. The place to communicate drug use activity with pharmacies is as a component of on-line, real-time electronic point-of-sales claims management. The department's focus is expansion of our electronic claims processing (ECP) system to accommodate more than data claims transmission. Our information system capabilities will have to be expanded in order to handle the transmission of more information back to the providers. Additionally, our own AVRS process under development will be an enhancement to the system and will improve communications about the medications we choose to prior approve.

If you have any questions, please contact Jim Donkin, Chief Internal Auditor at (217) 782-1156.

Sincerely,

[Signature]

Phil Bradley

c: Chester Stroyny